

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

CLARK et al.

Atty. Ref.: 620-432

Serial No. 10/576,095

Group: 1626

Filed: April 14, 2006

Examiner: Shameem

For: FURAN DERIVATIVES AS EP4 RECEPTOR  
ANTAGONISTS

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

October 17, 2008

Sir:

INFORMATION DISCLOSURE STATEMENT

- 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits] N/C
- 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)] N/C
- 2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)] \$180.00
- 3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 is attached which includes art of record in U.S. Patent No. 7,417,068, which has been considered by the present Examiner therein. The Examiner is requested to contact the undersigned by telephone in the event the Examiner next reaches this application for Action and the listed art is not contained in the PTO IFW in the above.

This paper is submitted in accordance with:

5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]

6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and

a) The required Statement made in item 8 below; **or**

b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.

7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and

a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and

b) The required Statement is stated in item 8 below.

8. Statement under 37 CFR 1.97(e)

a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or

b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37

CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/  
B. J. Sadoff  
Reg. No. 36,663

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100